Global Nanotechnology Drug Delivery Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Nanotechnology drugs enhance the targeted delivery of drugs to specific cells, tissues, or organs in the body. It involves the design, development, and utilization of nanoparticles or nanoscale materials to deliver therapeutic agents in a controlled manner. Nanotechnology drug delivery has the potential to revolutionize healthcare by improving the efficacy and safety of drug treatments. It is an active area of research and development, with numerous nanotechnology-based drug delivery systems being investigated for various diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. The Nanotechnology Drug Delivery market is expanding because of factors such as the growing prevalence of cancer and genetic and cardiovascular diseases and growing preference for personalized medicines as well as the rising number of drug development activities across the world.
Demand for novel drugs with targeted delivery for various chronic diseases has increased primarily due to the rising prevalence of chronic diseases such as diabetes, cardiovascular, cancer disease. Diabetes is becoming more and more common among people worldwide. According to information from the International Diabetes Federation (IDF) Diabetes Atlas Tenth Edition 2021, 537 million persons (aged 20 to 79) were estimated to have diabetes in 2021. According to the same source, by 2030 there will be 643 million individuals worldwide living with diabetes, and by 2045 there will be 783 million. The demand for more technologically sophisticated drug delivery alternatives for treatment and diagnosis will undoubtedly rise as the prevalence of diabetes rises. In addition, the Global Cancer Observatory’s (Globocan) Statistics 2020 report that there were 19.3 million new cases of cancer worldwide in 2020,. The same source notes that cancer is becoming more common worldwide and predicts that by 2040, there would be 28.8 million new instances of cancer in people of both sexes. As a result, the growing incidence of chronic diseases stimulates the demand for drug delivery systems based on nanotechnology, promoting market expansion. Furthermore, the expansion of the market has also been assisted by growing developments in nanoscale technologies and research & development efforts. In July 2022, for instance, the EU Horizon 2020 B-SMART project tried to develop a unique technique for delivering RNA past the blood-cerebrospinal fluid barrier, enabling therapies to be given directly to the brain. Therefore, developments in nano drug delivery systems fuel market expansion. Moreover, increasing advancements in nanoscale technologies, and a rising number of investments in research and development activities is creating new opportunities for the market. However, the high cost of nanotechnology drug delivery techniques and stringent regulations for commercial introduction stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Nanotechnology Drug Delivery Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to rising prevalence of various diseases, the presence of key market players, rising number of investments in research and development activities, rising number of clinical trials and drug discoveries activities in the region as well as rising demand for personalized medicine in the region.
Major market players included in this report are:
Bristol Myers Squibb (Celgene Inc)
Cytimmune Sciences Inc
NanoCarrier Co Ltd
Taiwan Liposome Co
Recent Developments in the Market:
Ø In June 2022, Researchers at the Baker Heart and Diabetes Institute created and developed a novel nanoparticle drug delivery system that can diagnose and treat several ailments as well as significantly increase the efficacy of a medication used to treat atherosclerosis.
Ø In January 2022, Researchers at Case Western Reserve University developed nanoparticles that deliver clot-promoting enzymes to the bleeding site and then release them there to produce fibrin, the body’s meshlike component that is essential for stopping the bleeding, where it is needed.
Global Nanotechnology Drug Delivery Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Technology, Application, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below:
Middle East & Africa
Rest of Middle East & Africa